RLB Holdings and Kineta Announce Second Investment, and Partnership Focused on Program Advancement

  RLB Holdings and Kineta Announce Second Investment, and Partnership Focused
  on Program Advancement

Business Wire

SEATTLE -- February 5, 2013

RLB Holdings and Kineta are pleased to announce a new investment partnership
focused on accelerating development of Kineta’s clinical stage drug
candidates. The two drug programs funded by the investment partnership are
ShK-186, a novel immune-sparing targeted therapeutic focused on autoimmune
diseases and rOAS, a novel pan-viral therapeutic aimed at an array of
malicious viruses for which there are few effective therapies.

“RLB Holdings found a great gem in Kineta – a company executing an innovative
business strategy that also addresses the enormous global need for better and
safer medicines,” said Lydia Bartoszek, Managing Partner and co-founder of RLB
Holdings. “Ray and I personally spent a lot of time getting to know the team
in Seattle and studying their business. We discovered a high caliber operation
poised for growth,” added Ms. Bartoszek.

RLB Holdings is an investment firm internationally regarded for its success in
selecting and managing high yield investments. RLB holds major positions in a
diverse array of companies from the legendary New York Yankees to Glencore
International and Horseheads Sand & Transloading Terminal in the Marcellus
shale region.

“With two major investments in Kineta in a span of two months, RLB Holdings
has provided us with substantial funding power to make major clinical
advancements,” said Charles Magness, PhD, Kineta President and CEO.

RLB Holdings’ second investment, announced today, funds manufacturing of the
drug lot for Kineta’s forthcoming rOAS clinical trial. The drug candidate is a
novel, host-directed antiviral focused on influenza, West Nile virus, Dengue
fever and many other contagious pathogens. RLB Holdings made its initial
investment in Kineta in November of 2012 enabling completion of first in human
trials on ShK-186, Kineta’s autoimmune drug program. ShK-186 targets multiple
sclerosis, lupus nephritis among other chronic autoimmune diseases. ShK-186 is
one of two Kineta drug programs profiled in the current issue of National
Geographic magazine, (the second is focused on non-narcotic severe pain
relief). Kineta has raised more than $40 million since its launch in 2008.
Terms of the RLB Holdings investment were not disclosed.

ABOUT US

RLB Holdings is an investment firm founded in 2011 by Ray and Lydia Bartoszek
who co-lead the firm as managing partners. RLB has pursued a diversified
strategy of investing in transformative products and services across leading
edge sectors. RLB Holdings seeks to uncover valuable opportunities poised for
substantial growth and also provide positive economic and community benefit.
Select investments include: The New York Yankees, Glencore International,
Solutionpoint International, Horseheads Sand & Transloading Terminal, Crunch
Gyms, Simple Wishes and Kineta. More information is available at
www.RLB-Holdings.com.

Kineta, Inc. is a Seattle-based privately held biotechnology company
specializing in clinical advancement of high-need novel immunotherapeutic drug
candidates. Our world class scientists are pioneers in developing
life-changing classes of drugs. Kineta seeks to improve the lives of millions
of people suffering from an array of diseases. Kineta’s progressive business
model focuses on targeting unmet medical needs and rapid achievement of
important clinical milestones. For more information on Kineta visit our
website, www.Kinetabio.com.

NOTICE:

This document contains certain forward-looking statements, including without
limitation statements regarding Kineta’s plans for drug manufacturing and
clinical studies. You are cautioned that such forward-looking statements are
not guarantees of future performance and involve risks and uncertainties
inherent in Kineta’s business which could significantly affect expected
results, including without limitation progress of drug development, drug
manufacturing, clinical testing and regulatory approval, developments in raw
material and personnel costs, and legislative, fiscal, and other regulatory
measures. All forward-looking statements are qualified in their entirety by
this cautionary statement, and Kineta undertakes no obligation to revise or
update any forward-looking statement to reflect events or circumstances after
the issuance of this press release.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130205005679/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50553501&lang=en

Contact:

Kineta, Inc.
Meg O’Conor, Executive Director, Corporate Business Development, 206-251-8638
moconor@kineta.us
 
Press spacebar to pause and continue. Press esc to stop.